October 01, 2011
Clinical Exome Challenge
Whole exome sequencing unlocks a patient’s personal genetic code for the majority of the over 20,000 genes in the human genome. For patients with poorly understood genetic diseases, the technology is uniquely capable of uncovering the genetic basis of disease, which may aid diagnosis, provide prognostic information, and guide therapy currently unavailable to such patients.
Patient advocacy groups are invited to submit letters of interest for review. Full proposals will be requested from groups with meritorious letters, and a total of 99 exome sequences will be awarded to the top submissions. All clinical exome sequencing will be performed in GPS@WUSTL’s CAP accredited, CLIA certified clinical laboratories, and a clinical interpretation report will be issued to the responsible physician for each patient sequenced, if warranted.
GPS thanks Agilent Technologies for the contribution of reagents for this initiative. Thanks also to marketing partner 2e Creative for donating their services to help spread the word about the Rare99X Clinical Exome Challenge.
To learn more about the Rare99X Clinical Exome Challenge:
Website: Rare99X Clinical Exome Challenge site
Press Release: Rare99X Clinical Exome Challege Press Release
Contact us: firstname.lastname@example.org